ArticleFrontiers in immunology2026
Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dendritic cells play a critical role in immunity. Fms-related tyrosine kinase 3 ligand (FLT3L) is a cytokine that can promote the expansion and differentiation of bone marrow dendritic cells (DC) progenitors. RO7497987 (FLT3L-Fc) is a novel FLT3 agonist developed to extend the half-life of FLT3L and induce expansion of peripheral blood DC. Methods: This Phase Ia trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7497987 in healthy volunteers. Forty-four participants received RO7497987 as a single ascending dose (SAD, 0.7-70 mg) or multiple ascending doses (MAD, 7 or 21 mg, 21 days apart). Results: RO7497987 was safe and well-tolerated at all doses. The most common treatment-related adverse events (AE) were Grade 1 myalgia, headache, and lymphadenopathy, all of which resolved spontaneously. There were no Grade ≥ 3 AEs, serious AEs, or dose-limiting adverse events. Pharmacokinetic analysis showed dose-dependent increases in FLT3L-Fc C Conclusion: These findings aid the design of dosing regimens of RO7497987 as an immunomodulatory agent. Clinical trial registration: https://www.isrctn.com/ISRCTN92655801, identifier ISRCTN92655801.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.